Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan

Japanese Circulation Journal

Volumn 62, Issue 1, 1998, Pages 7-14

  Wakugami, Kiyoshi ^a,b   Iseki, Kunitoshi ^b   Kimura, Yorio ^a   Okumura, Koichiro ^a   Ikemiya, Yoshiharu ^c   Muratani, Hiromi ^a   Fukiyama, Koshiro ^a  

^a Third Department of Internal Medicine   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c Okinawa Gen Hlth Maintenance A   (Japan)

Author keywords

Acute myocardial infarction; Cholesterol; Epidemiology

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MULTIPLE REGRESSION; PROTEINURIA; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; CHOLESTEROL; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; RISK FACTORS;

EID: 0031916256     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.62.7     Document Type: Article

References (38)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977; 62: 707-714
2. Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease. Ann Intern Med 1979; 90: 85-91
3. Castelli WP: Epidemiology of coronary heart disease: The Framingham Study. Am J Med 1984; 76: 4-12
4. Multiple Risk Factor Trial Research Group: Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA 1990; 263: 1795-1801
5. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med 1992; 152: 56-64
6. Pooling Project Research Group: Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis 1978; 31: 201-306
7. Butler WJ, Ostrander LD, Carman WJ, Lamphiear DE: Mortality from coronary heart disease in the Tecumset study: long-term effect of diabetes mellitus, glucose intolerance, and other risk factors. Am J Epidemiol 1985; 121: 541-547
8. Chapman JM, Massey FJ: The interrelationship of serum cholesterol, hypertension, body weight, and risk of coronary disease: results of the first ten years' follow-up in the Los Angeles Heart Study. J Chronic Dis 1964; 17: 933-949
9. Tyroler HA: Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation 1987; 76: 515-522
10. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al: Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-133
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mcfarlane PW, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307
12. The Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
13. Ueshima H, Tanaka K, Asakura S: Declining mortality from ischemic heart disease and changes in coronary risk factors in Japan, 1956-1980. Am J Epidemiol 1987; 125: 62-72
14. Shimamoto T, Komachi Y, Inada H, Doi M, Iso H, Sato S, et al: Trends for coronary heart disease and stroke and their risk factors in Japan. Circulation 1989; 79: 503-515
15. Toshima H: Coronary artery disease trends in Japan. Jpn Circ J 1994; 58: 166-172
16. Goto Y: Effects of alpha- and beta-blocker antihypertensive therapy on blood lipids: a multicenter trial. Am J Med 1984; 76: 72-78
17. Barmot MG, Smith GD: Why are the Japanese living longer? Br Med J 1989; 299: 1547-1551
18. Iseki K, Iseki C, Ikemiya Y, Fukiyama K: Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996; 49: 800-805
19. Iseki K, Ikemiya Y, Fukiyama K: Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney Int 1996; 49(Suppl 55): S69-S71
20. Kinjo K, Kimura Y, Shinzato Y, Kawazoe N, Takishita S, Fukiyama K, and COSMO Group: An epidemiological analysis of cardiovascular disease in Okinawa, Japan. Hypertens Res 1992; 15: 111-119
21. Iseki K, Miyasato F, Oura T, Uehara H, Nishime K, Fukiyama K: An epidemiologic analysis of end-stage lupus nephritis. Am J Kidney Dis 1994: 23: 547-554
22. WHO MONICA Project, Principal Investigators: WHO MONICA Project: assessing CHD mortality and morbidity. Int J Epidemiol 1989; 18(Suppl 1): S38-S45
23. SAS/STAT, User's Guide, Release 6.03. Cary, NC: SAS Institute, 1988
24. Blackburn H, Jacobs Jr DR: The ongoing natural experiment of cardiovascular disease in Japan. Circulation 1989; 79: 718-720
25. Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K: Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation 1996; 94: 61-66
26. Yano K, MacLean CJ, Reed DM, Shimizu Y, Sasaki H, Kodama K, et al: A comparison of the 12-year mortality and predictive factors of coronary heart disease among Japanese men in Japan and Hawaii. Am J Epidemiol 1988; 127: 476-487
27. Worth RM, Kato H, Rhoads GG, Kagan A, Syme SL: Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: Am J Epidemiol 1975; 102: 481-490
28. Wolfe RA, Strawderman RT: Logical and statistical fallacies in the use of Cox regression models. Am J Kidney Dis 1996; 27: 124-129
29. Grundy SM: HMG-CoA reductase inhibitors for treatment of hyper-cholesterolemia. N Engl J Med 1988; 319: 24-32
30. Marcelino JJ, Kenneth PD, Feingold KR: Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-610
31. Ministry of Health and Welfare: Report of smoking and health. Ministry of Health and Welfare, Tokyo, 1987 (in Japanese)
32. Omae T, Ueda K: Editorial review. Hypertension and cerebrovascular disease - the Japanese experience. J Hypertens 1988; 6: 343-349
33. Sacks FM, Pfeffer MA, Move LA, Rouleau JL, Rutherford JD, Cole TG, et al, for The Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009
34. Oliver MF: Might treatment of hypercholesterolemia increase non-cardiac mortality? Lancet 1991; 337: 1529-1531
35. Hulley SB, Walsh JMB, Newman TB: Health policy on blood cholesterol: time to change directions. Circulation 1992; 86: 1026-1029
36. The Pravastatin Multinational Study Group for Cardiac Risk Patients: Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus 2 additional atherosclerotic risk factors. Am J Cardiol 1993; 72: 1031-1037
37. Menotti A, Jacobs DR, Blackburn H, Kromhout D, Nissinen A, Nedelikevic S, et al: Twenty-five-year prediction of stroke deaths in the Seven Country Study. Stroke 1996; 27: 381-387
38. Shimamoto T, Iso H, Iida M, Komachi Y: Epidemiology of cerebrovascular disease: stroke epidemic in Japan. J Epidemiol 1996; 66: S43-S47